Abstract
BackgroundImmune checkpoint inhibitors (ICI) induce a range of immune-related adverse events (irAEs) with various degrees of severity. While clinical experience with ICI retreatment following clinically significant irAEs is growing, the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have